Literature DB >> 1333899

Significance of multidisciplinary therapy for hepatocellular carcinoma.

Y Kawarada1, T Imai, M Iwata, H Yokoi, T Noguchi, R Mizumoto.   

Abstract

The effect of multidisciplinary therapy for hepatocellular carcinoma (HCC) was evaluated in 121 resected cases. The 5-year survival was 100% for absolute curative resection (12 cases), 59.1% for relative curative resection (n = 37) and 10.9% for relative non-curative resection (n = 59). However, none of the patients survived for more than 3 years after absolute non-curative resection (n = 13). The non-recurrence in the preoperative TAE groups was different from that in non-TAE groups undergoing absolute and relative curative resection. The 1- and 3-year non-recurrence rates for relative non-curative resection were 92.3% and 53.8%, respectively, for the preoperative TAE group and 56.1% and 28.1%, respectively for the non-TAE group. These data show that preoperative TAE is effective in relative non-curative resection. Functional disturbances of the coagulation-fibrinolysis system in cirrhotic patients were improved after PSE. All patients undergoing hepatectomy after PSE had an uneventful postoperative course, including well-maintained function of the coagulation-fibrinolysis system and a decrease in splenic volume. At 1 year after hepatectomy, cirrhotic patients with critical liver function and poor coagulation-fibrinolysis showed appreciable hepatic regeneration. One patient died of hepatic failure 1 year after the operation. In recurrent HCC, the 1-, 2- and 3-year survival values after reresection were 100%, 75.0% and 25.0%, respectively. The respective values following TAE were 79.0%, 42.0% and 9.0%. Three cases of recurrent HCC were effectively treated, i.e., two patients achieved a partial response and one showed no change, by continuous intra-arterial infusion of 5-FU and lentinan with intermittent one-shot injections of epirubicin using a subcutaneous infusion pump. These three patients are alive at 1 year and 7 months, 1 year and 4 months and 6 months after the treatment, respectively.

Entities:  

Mesh:

Year:  1992        PMID: 1333899     DOI: 10.1007/bf00687098

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  Percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma.

Authors:  S Shiina; K Tagawa; T Unuma; A Terano
Journal:  AJR Am J Roentgenol       Date:  1990-05       Impact factor: 3.959

2.  A pre-operative chemoembolization therapy using lipiodol, cisplatin and gelatin sponge for hepatocellular carcinoma.

Authors:  S Imaoka; Y Sasaki; T Shibata; M Fujita; H Kasugai; J Kojima; S Ishiguro; H Ohigashi; O Ishikawa; I Fukuda
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Second hepatic resection for recurrent hepatocellular carcinoma.

Authors:  N Nagasue; H Yukaya; Y Ogawa; Y Sasaki; Y C Chang; K Niimi
Journal:  Br J Surg       Date:  1986-06       Impact factor: 6.939

4.  Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells.

Authors:  K Okuno; H Takagi; T Nakamura; Y Nakamura; Z Iwasa; M Yasutomi
Journal:  Cancer       Date:  1986-09-01       Impact factor: 6.860

5.  Intratumor injection of absolute ethanol under ultrasound guidance for the treatment of small hepatocellular carcinoma.

Authors:  J C Sheu; J L Sung; G T Huang; D S Chen; P M Yang; M Y Lai; T C Wei; C T Su; Y M Tsang; C Z Lee
Journal:  Hepatogastroenterology       Date:  1987-12

6.  Treatment of hepatic cancer by hepatic arterial infusion chemotherapy.

Authors:  T Miura
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Preoperative estimation of operative risk in liver surgery, with special reference to functional reserve of the remnant liver following major hepatic resection.

Authors:  R Mizumoto; Y Kawarada; T Noguchi
Journal:  Jpn J Surg       Date:  1979-12

8.  Ultrasonically guided percutaneous ethanol injection therapy for hepatocellular carcinoma.

Authors:  T Seki; T Nonaka; Y Kubota; T Mizuno; Y Sameshima
Journal:  Am J Gastroenterol       Date:  1989-11       Impact factor: 10.864

9.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

10.  Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients.

Authors:  M Ebara; M Ohto; N Sugiura; K Kita; M Yoshikawa; K Okuda; F Kondo; Y Kondo
Journal:  J Gastroenterol Hepatol       Date:  1990 Nov-Dec       Impact factor: 4.029

View more
  4 in total

1.  Changes in portal hemodynamics and hepatic function after partial splenic embolization (PSE) and percutaneous transhepatic obliteration (PTO).

Authors:  M Mukaiya; K Hirata; K Yamashiro; T Katsuramaki; H Kimura; R Denno
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Surgical treatment of hepatocellular carcinoma.

Authors:  Y Kawarada; F Ito; H Sakurai; K Tanigawa; M Iwata; T Imai; H Yokoi; T Noguchi; R Mizumoto
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Prognosis after hepatic resection in patients with hepatocellular carcinoma, estimated on the basis of the morphometric indices.

Authors:  Y Kawai; K Takeshige; M Nunome; H Kuroda; H Suzuki; K Banno; T Koide; H Kobayashi; Y Owa; A Koike
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Treatment of choice for unresectable small liver cancer: percutaneous ethanol injection therapy or transarterial chemoembolization therapy.

Authors:  Y Horiguchi; B Sekoguchi; H Imai; T Suzuki; H Kubo; H Itoh; M Itoh
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.